Celltrion, Inc., a leading global biopharmaceutical company, recently announced that its infliximab biosimilar will be marketed in Canada under the new brand name Remdantry starting April 1, 2025, following approval of the product name change by Health Canada.
As Remdantry uses the same Drug Identification Number (DIN) as Inflectra, the formulation, indications and dosages of Remdantry will remain the same as that of Inflectra, which was originally approved by the Health Canada for the treatment of rheumatoid arthritis (RA), plaque psoriasis (PsO), psoriatic arthritis (PsA), and ankylosing spondylitis (AS) in January 2014 and for Crohn’s disease (CD), fistulising Crohn’s disease and ulcerative colitis (UC) in June 2016.
“For patients with chronic inflammatory diseases requiring long-term treatment, especially those who are currently well-managed, the idea of switching to a different biosimilar can be a sensitive issue,” said Dr. Brian Bressler, MD, MS, FRCPC Head, Division of Gastroenterology, Providence Health Care, University of British Columbia. “It is reassuring to know that while the product name is changing from Inflectra to Remdantry, the medication itself remains exactly the same. Patients who have been on Inflectra can continue their therapy without any need to switch between different biosimilars, ensuring consistency in their care during this transition.”
Celltrion developed and manufactured the world’s first monoclonal antibody biosimilar, followed by the first and only subcutaneous (SC) formulation infliximab, ‘Remsima SC’, which was also approved in Canada for the treatment of RA, for maintenance therapy in adults with moderately to severely active ulcerative colitis (UC) and Crohn’s disease (CD).
“Our priority is ensuring a seamless transition for patients and healthcare providers,” said Jungyong Shin, Managing Director at Celltrion Healthcare Canada. “The introduction of Remdantry reflects Celltrion’s consolidation of both the intravenous (IV) and subcutaneous (SC) formulations under our direct commercialization. By doing so, we aim to provide healthcare professionals with a more streamlined prescribing experience, reducing complexity in treatment decisions, while supporting improved patient access to optimal, personalized care.”
During this transition, Celltrion is committed to ensuring continued patient support through its patient support program (PSP). Both brand names – Inflectra and Remdantry – will be available under the same DIN for a six-month phase-in period and healthcare providers can still prescribe Remdantry as Inflectra. After the transition period, prescriptions will be exclusively issued under the new brand name ‘Remdantry’.
Celltrion remains dedicated to delivering high-quality biosimilar therapies and supporting healthcare professionals and patients throughout this transition.
If you want to visit similar news, you can go through these pages:
Hologic Announces Martin Madaus as Member of Its Board of Directors
Sequentia Biotech Secures Euro 10Mn Equity Investment From Seventure Partners and EIC Fund
